Please provide your email address to receive an email when new articles are posted on . A literature search identified 70 eyes with retinal vasculitis or vascular occlusion following brolucizumab for ...
SEATTLE -- Reports of unexpected panuveitis and retinal occlusive vascular disease associated with pegcetacoplan (Syfovre) treatment has triggered a search for answers by ophthalmologists and the drug ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — An analysis of a large series of cataract surgeries found no association between hemorrhagic occlusive ...
The American Society of Retina Specialists (ASRS) has received reports of at least six cases of occlusive retinal vasculitis following injection of pegcetacoplan (Syfovre) into the eye. In an email to ...
A retrospective case series suggested that faricimab (Vabysmo) intravitreal injections may be associated with rare cases of noninfectious intraocular inflammation. Over a 22-month period, 12 eyes from ...
SEATTLE — "Falsely reassuring" is how one retina specialist characterized an extension study of pegcetacoplan that found no cases of occlusive retinal vasculitis after 23,000 injections into eyes. A ...
– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results